Protagonist Therapeutics Grants 55,425 Options at $105.44 Plus 14,425 RSUs
On April 15, 2026, Protagonist Therapeutics granted 55,425 stock options at a $105.44 exercise price and 14,425 restricted stock units to two new hires under its amended inducement plan. These awards vest over four years and were approved by the compensation committee as material inducements per Nasdaq rules.
1. Inducement Awards Granted
Protagonist Therapeutics issued inducement awards on April 15, 2026 to two newly hired employees, comprising options to purchase 55,425 shares and RSUs for 14,425 shares. The option exercise price was set at $105.44 per share, matching the closing price on the grant date.
2. Vesting Schedule and Approval
The options vest 25% after one year of service with the remainder vesting in equal monthly installments over the following three years, while RSUs vest 25% annually over four years. These grants were approved by the compensation committee as material inducements under Nasdaq Marketplace Rule 5635(c)(4).
3. Inducement Plan Background
Awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, originally adopted in May 2018 and amended in February 2020 and 2022. The plan is designed to attract key talent by aligning equity incentives with long-term shareholder value.